SPYRE THERAPEUTICS INC (SYRE)
US00773J2024 - Common Stock
SYRE Crosses Above Key Moving Average Level
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody...
SYRE Makes Notable Cross Below Critical Moving Average
Spyre Therapeutics to Participate in Upcoming Investor Conference
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational...
Bullish Two Hundred Day Moving Average Cross - SYRE
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024
SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spyre Therapeutics (NASDAQ:SYRE) just reported results for the second quarter o...
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept...
Commit To Buy Spyre Therapeutics At $20, Earn 15.7% Annualized Using Options
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Notable Two Hundred Day Moving Average Cross - SYRE
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024
SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spyre Therapeutics (NASDAQ:SYRE) just reported results for the first quarter of...
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Announces $180 Million Private Placement
/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics GAAP EPS of -$4.05 (NASDAQ:SYRE)
Read about Spyre Therapeutics' latest financial results and find out their Q4 GAAP EPS of -$4.05 in our press release.
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the...
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics appoints Mark C. Mckenna to its Board (NASDAQ:SYRE)
Spyre Therapeutics announces appointment of Mark C. McKenna to its Board of Directors.
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...
3 Best Stocks to Buy Now,4, According to Top Analysts
Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a n...
Spyre Therapeutics Announces Grants of Inducement Awards
/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...
Spyre Therapeutics to sell 12M shares for holders (NASDAQ:SYRE)
Spyre Therapeutics (SYRE) files prospectus for resale of 12M shares by selling stockholders; it does not constitute an offer to sell securities.
Spyre Therapeutics announces $180 million private placement (NASDAQ:SYRE)
Spyre Therapeutics announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to re
Spyre Therapeutics Announces $180 Million Private Placement
/PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...